Status:
COMPLETED
Patients Preference With Self-Injection: The PRISM Study
Lead Sponsor:
Hamilton Health Sciences Corporation
Collaborating Sponsors:
St. Joseph's Health Care London
Conditions:
Bruises
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine which short-acting blood thinner (low-molecular-weight heparin \[Enoxaparin\] or unfractionated heparin) is associated with less discomfort and bruising when ...
Detailed Description
Increasing Patient Comfort and Compliance: The Bridging Anticoagulation Clinic strives to provide the highest quality of care to patients who require temporary interruption of warfarin therapy. An imp...
Eligibility Criteria
Inclusion
- Patient is receiving warfarin therapy with a target international normalized ratio (INR) of 2.0-3.5
- Patient requires temporary interruption of warfarin because of elective surgery or procedure.
Exclusion
- History of allergy to heparin, including heparin-induced thrombocytopenia (HIT)
- Bridging anticoagulation with low molecular weight heparin (LMWH) or unfractionated heparin (UFH) not indicated
- Impaired cognitive function or language barrier
- Creatinine clearance \< 30 ml/min
- Patient declines consent
- Patient is \< 18 years of age.
- Patient is not willing and able to self inject.
- Patient has significant visual or hand motor impairment
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2007
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00253396
Start Date
October 1 2005
End Date
January 1 2007
Last Update
March 10 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Joseph's Healthcare
Hamilton, Ontario, Canada, L8N 4A6